Saponin Based Adjuvants
Saponin-based adjuvants offer remarkable versatility for both human and veterinary vaccines. Recognized for their ability to enhance antigen presentation and stimulate cellular immunity, they play a vital role in modern vaccine development, supporting stronger, longer lasting, and more balanced immune protection across diverse applications.
Advancing Innovation in Vaccine Technologies
Through its partnership with Q-VANT Biosciences, SPI Pharma expands its vaccine adjuvant portfolio with sustainably sourced, biomass-derived saponins. This collaboration enables reliable, scalable production of high-purity QS-21 for human use and QSap™ VET for veterinary applications, ensuring consistent quality and global supply security.
Our Portfolio
QS-21 XP
QS-21 XP is a highly purified QS-21 fraction (>95% purity) derived from a scalable and sustainable biomass source. QS-21 is a critical adjuvant component in multiple FDA- or WHO-approved vaccines, including Mosquirix® (malaria), Shingrix® (varicella-zoster), and Arexvy® (RSV), and is currently being evaluated in numerous human vaccine candidates.
QS-21 GH
QS-21 GH is a purified, cost-effective QS-21 fraction produced from a scalable and sustainable Quillaja biomass source, offering open-access availability to support next-generation vaccine development.
QSap™ VET
QSap VET is an immunomodulatory adjuvant for veterinary use composed of the complete saponin profile from Quillaja saponaria. QSapTM VET is made from renewable plant biomass employing an industrial manufacturing process that guarantees batch-to-batch consistency in saponin composition.
